Designation of Bosentan as an orphan drug - Amneal Pharma Australia

Overview

The Therapeutic Goods Act 1989 was enacted to provide a regulatory framework for therapeutic goods in Australia, aiming to ensure that these goods are of acceptable quality, safety, and efficacy. The Act was introduced to address the need for a comprehensive regulatory system governing the manufacture, import, supply, and advertising of therapeutic goods to protect public health. Enacted by the Commonwealth Parliament, the policy objective of the Act is to safeguard the health and safety of Australians by regulating therapeutic goods through a risk-based approach. On 17 May 2016, Dr. Anthony Gill, acting as the Delegate of the Secretary under subregulation 16J(2) of the Therapeutic Goods Regulations 1990, designated Bosentan as an orphan drug for the treatment of specified pulmonary arterial hypertension conditions. This designation aims to encourage the development and availability of treatments for rare diseases by offering certain incentives and support to sponsors of orphan drugs, in this case, Amneal Pharma Australia Pty Ltd, to ensure that patients with these rare conditions have access to necessary medications.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) within the Commonwealth of Australia, provides the legal framework for the regulation of therapeutic goods. The designation of Bosentan as an orphan drug under this Act pertains to specific medical treatments, particularly for rare conditions such as idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma, and pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including Eisenmenger’s physiology. This designation applies to patients who exhibit WHO functional Class II, III, or IV symptoms and underscores the TGA’s commitment to ensuring access to vital treatments for rare diseases. The Act’s application is geographically comprehensive, covering the entire Commonwealth, and its regulatory scope is extended through the Therapeutic Goods Regulations 1990, which facilitate detailed governance of therapeutic goods including their designation, approval, and monitoring. Exclusions and exemptions from certain regulatory requirements are outlined within the Regulations, which may include provisions for clinical trials and manufacturing standards. The scope of the Act is further refined through subordinate instruments, ensuring precise and effective regulation of therapeutic goods in Australia.

Key Provisions

The main operative sections of the Therapeutic Goods Act 1989, as applied in this Gazette, include sections that empower the designation of specific therapeutic goods under particular conditions. In this instance, section 16J of the Therapeutic Goods Regulations 1990 (subregulation 16J(2)) provides the authority for designating a drug as an orphan drug. According to this section, Dr. Anthony Gill, as the Delegate of the Secretary, has designated Bosentan as an orphan drug for the treatment of certain forms of pulmonary arterial hypertension, specifically idiopathic, familial, associated with scleroderma, and associated with congenital systemic to pulmonary shunts, including Eisenmenger's physiology, in patients with WHO functional Class II, III, or IV symptoms. The drug must be in the form of a film-coated tablet, and Amneal Pharma Australia Pty Ltd is identified as the sponsor. The obligations and requirements imposed by the Act on the parties involved include ensuring that the designated orphan drug meets all regulatory standards for safety, efficacy, and quality. The sponsor, Amneal Pharma Australia Pty Ltd, is responsible for providing all necessary data and information to support the orphan drug designation. They must ensure that the drug is manufactured according to Good Manufacturing Practice (GMP) standards and that any claims made about the drug are substantiated by scientific evidence. Additionally, the sponsor must comply with ongoing reporting requirements and maintain records as stipulated by the Therapeutic Goods Administration (TGA). Any breaches of the obligations or requirements set out in the Therapeutic Goods Act 1989 or the Therapeutic Goods Regulations 1990 can result in significant consequences. Under section 27 of the Act, individuals or entities found to have contravened the regulations may face civil penalties, including fines of up to $222,200 for a corporation and $44,440 for an individual, depending on the severity and nature of the breach. In more serious cases, criminal penalties may apply, including imprisonment for up to five years for individuals. Additionally, the TGA has the authority to take various enforcement actions such as product recalls, suspension of approvals, or cancellation of registrations, which can severely impact the sponsor's ability to market the therapeutic product in Australia.